Cingulate Inc. (CING)
4.12
-0.04 (-0.96%)
At close: Apr 03, 2025, 3:58 PM
3.99
-3.08%
After-hours: Apr 03, 2025, 07:56 PM EDT
Company Description
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder.
The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders.
It also focuses on developing CTx-2103 for the treatment of anxiety disorders.
The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Cingulate Inc.
| Country | United States |
| IPO Date | Dec 8, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Dr. Raul R. Silva M.D. |
Contact Details
Address: 1901 West 47th Place Kansas City, Kansas United States | |
| Website | https://www.cingulate.com |
Stock Details
| Ticker Symbol | CING |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001862150 |
| CUSIP Number | 17248W105 |
| ISIN Number | US17248W2044 |
| Employer ID | 86-3825535 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Raul R. Silva M.D. | Co-Founder, Executive Vice President & Chief Science Officer |
| Thomas Dalton | Vice President of Investor & Public Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 26, 2025 | 8-K | Current Report |
| Mar 04, 2025 | 8-K | Current Report |
| Feb 20, 2025 | 4 | Filing |
| Feb 20, 2025 | 4 | Filing |
| Feb 20, 2025 | 4 | Filing |
| Feb 20, 2025 | 4 | Filing |
| Feb 20, 2025 | 4 | Filing |
| Feb 03, 2025 | 8-K | Current Report |
| Jan 24, 2025 | 8-K | Current Report |